NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Zymeworks Inc. ZYME
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$106.0M
▲ 38.9% vs FY2024
EPS · FY25
$-1.08
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-26.7%
Net margin · FY25
-76.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 106.0M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 77 cents on every revenue dollar this year.
Per share
USD -1.08
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-26.7%
Return on equity, FY2025
ROE
Operating margin-87.3%
Net margin-76.6%
Return on assets-20.0%
Each USD of equity lost 27 cents this year.
Returned to shareholders
USD 41.7M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 41.7M
Share of profit-51.4%
Consecutive raises—
USD 41.7M in buybacks went back to shareholders in a year without profit.
Growth
+22.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−36.4%
+22.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 346.5M
total assets, end of FY2025
Total assetsUSD 346.5M
EquityUSD 268.5M
CashUSD 41.2M
Current ratio5.88×
Equity funds 77% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.1
0.1
0.1
0.4
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
0.1
−0.2
−0.2
EBITDA $B
−0.1
−0.1
−0.1
0.1
−0.2
−0.2
Income tax $B
0.0
0.0
−0.0
0.0
−0.0
0.0
Net income $B
−0.1
−0.1
−0.1
0.1
−0.2
−0.2
EPS, diluted $
−1.08
−1.62
−1.72
1.90
−4.61
−3.58
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−26.7
−30.5
−24.8
33.5
−64.3
−44.0
Shares out B
0.07
0.07
0.07
0.06
0.05
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
16 of 16
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed